Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:ATCCode |
none (not assigned)
|
| gptkbp:CASNumber |
913376-84-8
|
| gptkbp:clinicalTrialPhase |
Phase 3 (as of 2023)
|
| gptkbp:developedBy |
gptkb:Minerva_Neurosciences
|
| gptkbp:hasMolecularFormula |
C22H23FN4O2
|
| gptkbp:hasSMILES |
C1CN(CCC1N2C=CC=CC2=O)CCN3CCC(CC3)C4=CC(=NO4)F
|
| https://www.w3.org/2000/01/rdf-schema#label |
roluperidone
|
| gptkbp:intendedUse |
treatment of negative symptoms of schizophrenia
|
| gptkbp:IUPACName |
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-1H-quinolin-2-one
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
5-HT2A receptor antagonist
alpha1A-adrenergic receptor antagonist sigma2 receptor antagonist |
| gptkbp:molecularWeight |
394.44 g/mol
|
| gptkbp:PubChem_CID |
25154816
CHEMBL2103887 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
MIN-101
|
| gptkbp:UNII |
6Z5B6E6EZE
|
| gptkbp:bfsParent |
gptkb:Minerva_Neurosciences
|
| gptkbp:bfsLayer |
7
|